Enanta Pharmaceuticals, Inc. (ENTA), a clinical-stage biotechnology firm, announced on Monday promising topline outcomes from their Phase 2 trial assessing the efficacy of zelicapavir in treating respiratory syncytial virus (RSV). This news led to a rise of over 4% in the company's pre-market share value.
The study, which was performed in two segments involving pediatric patients aged 28 days to 36 months with RSV, revealed that zelicapavir achieved a viral load reduction of 1.2 log compared to placebo by day 5. Furthermore, zelicapavir was well-received, exhibiting a favorable safety profile.
On Friday, Enanta's stock concluded at $8.00, reflecting a decrease of 0.12%. Over the past year, the stock has fluctuated between $7.86 and $17.80.
